Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

Ibuprofen or piroxicam protects nigral neurons and delays the development of l -dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis

(2016) Asmaa M. Teema et al.   NEUROPHARMACOLOGY

A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat

(2016) Ling Han et al.   NEUROREPORT

Ret is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in a Parkinson disease mouse model

(2016) Anja Drinkut et al.   Cell Death & Disease

Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells

(2016) Hanaa H Ahmed et al.   World Journal of Stem Cells

Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice

(2016) Takuo Nagai et al.   PLoS One

Gliptin and GLP‐1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide‐induced endotoxemia

(2015) Sebastian Steven et al.   BASIC RESEARCH IN CARDIOLOGY

Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

(2015) Li-Hui Zhang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways

(2015) Rania M. Abdelsalam et al.   JOURNAL OF NEUROCHEMISTRY

Saxagliptin: A novel antiparkinsonian approach

(2015) Noha N. Nassar et al.   NEUROPHARMACOLOGY

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway

(2014) Yao Dai et al.   CARDIOVASCULAR DRUGS AND THERAPY

Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice

(2014) Si GOU et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals

(2014) Catarina Marques et al.   MEDIATORS OF INFLAMMATION

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes

(2014) André J. Tremblay et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism

(2013) D. Wang et al.   DIABETES

Parkinson disease: from pathology to molecular disease mechanisms

(2013) David T. Dexter et al.   FREE RADICAL BIOLOGY AND MEDICINE

Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction

(2013) Yen-Ta Chen et al.   Journal of Translational Medicine

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

(2013) Young-Sun Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model

(2013) Vadivel Parthsarathy et al.   PLoS One

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

GLP-1 secretion by microglial cells and decreased CNS expression in obesity

(2012) Camilla Kappe et al.   Journal of Neuroinflammation

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity

(2011) Amany A. Abdin et al.   NEUROSCIENCE RESEARCH

Acetyl-l-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy

(2011) Sawsan A. Zaitone et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection

(2010) Alexander Harkavyi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Functional pancreatic beta-cell mass: Involvement in type 2 diabetes and therapeutic intervention

(2009) M. Karaca et al.   DIABETES & METABOLISM

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

(2009) Sehee Kim et al.   JOURNAL OF ENDOCRINOLOGY

A highly reproducible rotenone model of Parkinson's disease

(2009) Jason R. Cannon et al.   NEUROBIOLOGY OF DISEASE